Scandinavian ChemoTech’s TSE technology gives hope to horses suffering from sarcoids
Today the ESVONC congress in Syracuse, Italy, opens. In a poster, presented at the congress, the Tumour Specific Electroporation - TSE™ treatment of a horse is outlined and described as showing outstanding results.
The author of this poster is DVM (Doctor in Veterinary Medicine) Majbritt M E Larsen, Specialist in small animal internal medicine and head of Oncology at Evidensia Specialistdjursjukhuset Helsingborg.
The title of the poster is: “Treatment of equine sarcoids using intratumoral Bleomycin in combination with Tumour Specific Electroporation - TSE™” and describes the outstanding result of treatment of a 15-year-old horse with 9 sarcoids. The horse was treated once and is now in complete remission.
Surgery on sarcoids gives often only a short-term solution as the sarcoids usually return and sometimes also spread to new places. Sarcoids are skin tumours that are locally invasive but do not spread to other organs, it is a fibrosarcoma and account for 40 percent of all equine cancers.
“Complete remission was achieved in 9/9 sarcoids within the current observation period of 30 weeks. Toxicity was limited, with two lesions exhibiting grade 3 toxicity and seven lesions exhibiting grade 1-2 toxicity.” - writes DVM Majbritt M E Larsen in the poster
“We are very happy with this result which gives many horse owners an effective and easy treatment, to a disease that is known to be difficult to treat.” -says Elin Wallin Product specialist at Vetiqure AB
The complete poster will be published on Scandinavian ChemoTech´s and Vetiqure’s respective websites after the congress.
For further information please contact: Mohan Frick, CEO
+46 (0)10-218 93 00
info@chemotech.se
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation (TSE™), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.
